Detection of antineutrophil cytoplasmic antibodies (ANCA) for ANCA-associated vasculitides (AAV) is based on indirect immunofluorescence (IIF) on ethanol-fixed neutrophils and reactivity toward myeloperoxidase (MPO) and proteinase 3 (PR3). According to the international consensus for ANCA testing, presence of ANCA should at least be screened for by IIF and, if positive, followed by antigen-specific immunoassays. Optimally, all samples are analyzed by both IIF and quantitative antigen-specific immunoassays. Since the establishment of this consensus many new technologies have become available and this has challenged the positioning of IIF in the testing algorithm for AAV. In the current paper, we summarize the novelties in ANCA diagnostics and discuss the possible implications of these developments for the different ANCA algorithms that are currently applied in routine diagnostic laboratories. Possible consequences of replacing ANCA assays by novel methods are illustrated by our data obtained in daily clinical practice. Eventually, it is questioned if there is a need to change the consensus, and if so, whether IIF can be discarded completely, or be used as a confirmation assay instead of a screening assay. Both alternative options require that ANCA requests for AAV can be separated from ANCA requests for gastrointestinal autoimmune diseases. Lupus (2016) 25, 917-924.
Introduction
Antineutrophil cytoplasmic antibodies (ANCA) have been recognized as clinically relevant autoantibodies for more than 50 years. 1 ANCA were originally detected by indirect immunofluorescence (IIF) on ethanol-fixed neutrophils revealed as two major patterns: granular cytoplasmic staining (C-ANCA), or perinuclear staining (P-ANCA). Although ANCA can be found in multiple autoimmune diseases, the recognition that proteinase 3 (PR3) and myeloperoxidase (MPO) are the dominant autoantigens in small-vessel vasculitis has linked ANCA testing with the so-called ANCAassociated vasculitides (AAV; granulomatosis with polyangiitis, microscopic polyangiitis, and eosinophilic granulomatosis with polyangiitis). However, ANCA with other, less well-defined antigen specificities are also of added value in the diagnosis of inflammatory bowel diseases and autoimmune liver diseases. At the end of the previous century, an international consensus was published about the appropriate detection and reporting of ANCA for the respective disease entities. 2, 3 For AAV, the minimal requirements include screening with IIF on ethanol-fixed neutrophils, and if positive, followup with antigen-specific enzyme-linked immunosorbent assays (ELISAs) enabling detection of PR3-and MPO-ANCA ( Figure  1(a) ). Preferentially, all diagnostic samples are tested both by IIF and ELISA in a (semi)quantitative way (Figure 1(b) ). This consensus was largely eminence based, but also strongly supported by a multicenter study. 4 A meta-analysis confirmed that the results obtained by the consensus algorithm have the best diagnostic performance for AAV, 5 i.e. with a sensitivity of 84.7% and a specificity of 98.6%, the combination of P-ANCA/MPO-ANCA or C-ANCA/PR3-ANCA give a high diagnostic accuracy for a relatively rare disease. Although the results of the ANCA tests are not included in the current disease criteria, 6, 7 it is well recognized that inclusion of ANCA in novel definitions and criteria is warranted. 8, 9 Since the start of the new millennium, several new developments have been introduced for appropriate ANCA detection. With respect to IIF technologies, reading of IIF slides has been automated 10, 11 and the analysis of ANCA-specificity for MPO and PR3 has been combined with the traditional IIF in a single assay. 11, 12 Also, other immunoassays for determining ANCA-specificity have been developed: fluorescent-enzyme immunoassays (FEIA), addressable laser bead immunoassays (ALBIA), chemiluminescent immunoassays (CLIA), and dot or line immunoassays (DIA/ LIA). [13] [14] [15] [16] [17] [18] Originally all these assays had in common that the antigens, purified from human neutrophils, were directly linked to the carrier of the assay. These assays are referred to as direct or first-generation assays. To further improve the sensitivity for AAV, the application of capturing antibodies was applied to the method of ANCA detection. 19 These so-called capture immunoassays (second-generation assays) have the advantage that the conformation of the antigen is better retained. Hence, the antigen is better recognized by the autoantibodies resulting in increased sensitivity. Furthermore, an additional purification is performed within the assay, predicting a better specificity. Although it should be kept in mind that test characteristics like sensitivity and specificity are highly dependent on the chosen cut-off, 20 it has been established that capture ELISAs for PR3-ANCA are more sensitive than direct ELISAs, 21 while specificity is considered to be improved both for MPO-and PR3-ANCA. 21, 22 More recently, a third approach to antigen binding has been introduced. This is the so-called anchor technology, also referred to as third-generation ANCA assays. [23] [24] [25] [26] In these assays, the antigen is coated to the carrier via an adaptor peptide. Similar to the second-generation assays, this results in increased sensitivity due to better presentation and recognition of the antigen. The specificity, however, is expected to be similar to the first-generation assays.
In the current manuscript we describe the consequences of these developments for the testing algorithm in routine and specialized laboratories. First, we present our data on the consequences of our in-house ANCA algorithm after replacement of first-generation ANCA assays by third-generation ANCA assays. Second, we discuss the position of ANCA IIF in the testing algorithm. Finally, we discuss standardization issues related to quantification of ANCA results.
The effect of ANCA test-replacement on the algorithm in clinical practice
Based on the current international consensus and the assay formats available at the start of the 21st century, ANCA detection in our clinical immunology laboratory was first performed in a multistage testing algorithm ( Figure 2 ). 13, 24 Sera of new patients were screened by IIF on ethanolfixed neutrophils, and if ANCA were detected, or detection was obscured by interfering antinuclear antibodies, first-generation assays both for PR3as well as MPO-ANCA were performed. If positive, the reactivity was confirmed by second-generation assays; the result of the latter assay was considered conclusive because of its higher specificity. Since second-generation PR3-ANCA assays have been reported to be more sensitive, all sera revealing a C-ANCA pattern by IIF were additionally analyzed by capture ELISA for PR3-ANCA. At the end of 2011, the first-generation assays were replaced by third-generation ANCA assays. As mentioned before, these third-generation assays are considered to have better test characteristics than first-generation assays. Therefore, it was questioned if the testing algorithm should be adjusted. We retrospectively examined whether (i) C-ANCApositive samples that are negative in third-generation PR3-ANCA assays still require testing in second-generation assays, and (ii) PR3-and MPO-ANCA detected by third-generation assays still require confirmation in second-generation assays.
Patient data were extracted from our hospital information system. Only the first ANCA request in our laboratory of each patient was included if the ANCA was requested two years before (2010-2011; n ¼ 3247) or two years after (2012-2013; n ¼ 2850) shifting from first-to third-generation assay. ANCA screening was performed by IIF technique on ethanol-fixed granulocytes (Inova Diagnostics, San Diego, CA, USA). Immunoassays used were: first-generation test (direct-FEIA; Thermo Fisher Scientific, Freiburg, Germany), second-generation test (Wieslab capture ELISA; Euro-Diagnostica, Malmo¨, Sweden) and third-generation test (anchor-FEIA; Thermo Fisher Scientific).
In order to answer the question whether secondgeneration assays for PR3-ANCA have added value in C-ANCA-positive samples that are negative in first-or third-generation assays, we examined the frequency of positive results obtained by second-generation assays ( Table 1 ). In the years 2010-2011, a total of 144 samples revealed a C-ANCA pattern; 27 samples (18.7%) were PR3-ANCA positive by the first-generation assay. Within the 117 (81.3%) negative samples only two (1.7%) were positive in the subsequent analysis in the second-generation PR3-ANCA assay. Similarly, in the years 2012-2013 a total of 84 samples revealed a C-ANCA pattern; 12 samples (14.3%) were PR3-ANCA positive by the thirdgeneration assay. Within the 72 (85.7%) negative samples only one (1.4%) was positive in the subsequent analysis in the second-generation PR3-ANCA assay. Two of the three patients, positive only in the second-generation PR3-ANCA ELISA, were referred from other hospitals and were already undergoing remission-induction therapy. This therapy may have resulted in a negative test result in the first-generation PR3-ANCA FEIA. No AAV was diagnosed for the third patient. These results suggest equal sensitivity of second-and third-generation assays. However, as compared to first-generation assays, the increased sensitivity of second-generation assays, apparently, is less evident in daily clinical practice.
The second question about the need for confirmation by second-generation immunoassays was answered by inclusion of all samples that tested positive for either MPO-or PR3-ANCA in the first-generation assays (2010-2011; n ¼ 53) and third-generation assays (2012-2013; n ¼ 48). A final diagnosis was not available in four and two patients, respectively, and these data were excluded from analysis. The results are presented in Table 2 . In the years 2010-2011, the ANCA specificity, as obtained in first-generation assays, was confirmed in 30 samples (64%); 23 of the respective patients (77%) were diagnosed with AAV. Importantly, in 17 samples (36%) the ANCA specificity could not be confirmed and in 16 of these patients (94%) a diagnosis other than AAV was made. These data illustrate that confirmation of results obtained by first-generation assays by second-generation assays results in a higher specificity of the testing algorithm, with minimal loss of sensitivity (n ¼ 1; 6%). In the years 2012-2013, the ANCA specificity, as obtained by third-generation assays, was confirmed in 34 samples (77%); 21 of the respective patients (62%) were diagnosed with AAV. In 10 samples (23%) the ANCA specificity was not confirmed and in nine of these patients (90%) the diagnosis The selection of samples is based on, respectively, PR3-and MPO-ANCA-positive results obtained by first-generation immunoassays (direct FEIA) and third-generation immunoassays (anchor FEIA) and was independent of the IIF ANCA pattern. Confirmation was performed by second-generation immunoassays (capture ELISA). A final diagnosis was not made in a three, b one, c two, and d four patients, respectively. ANCA: antineutrophil cytoplasmic antibodies; PR3: proteinase 3; C-ANCA: cytoplasmic staining; AAV: ANCA-associated vasculitides; IIF: indirect immunofluorescence; FEIA: fluorescent-enzyme immunoassays; MPO: myeloperoxidase; ELISA: enzyme-linked immunosorbent assay. Table 1 Detection of PR3-ANCA by second-generation assays in C-ANCA-positive samples that were negative in first- of AAV was not made. These data indicate that confirmation of ANCA results obtained by thirdgeneration immunoassays remains of added value. Therefore, our original algorithm ( Figure 2 ) was only adjusted with respect to testing all C-ANCA samples by second-generation PR3-ANCA assays.
Re-positioning of ANCA IIF in the algorithm
Because the second-and third-generation ANCA tests, in particular for PR3-ANCA, are thought to be more sensitive, two important issues had to be addressed. First, we questioned whether ANCA IIF still is of added value, and second, if screening with antigen-specific assays and follow-up of positive samples with ANCA IIF offers a good alternative (Figure 3(a) ). In the Netherlands, a questionnaire was designed to find out how ANCA testing is performed. 27 It appeared that in 2010 about 20% of the laboratories offering ANCA testing did not perform ANCA by IIF. Moreover, this percentage increased to 40% in subsequent years after broad introduction of third-generation ANCA assays. In the meantime, the same questionnaire was distributed in several European countries, as well as to several expert laboratories worldwide. Similar to the questionnaire about ANA testing, 28 the results of the ANCA questionnaires will eventually become available for the ANCA community (Damoiseaux et al., manuscript in preparation).
Preliminary results reveal that, for instance, in Austria the percentage of laboratories not performing IIF is 50% and in Italy is 25%, while in France only 1 out of 36 (3%) laboratories has discarded IIF from its ANCA algorithm. A small study indicates that a strategy based on screening for ANCA with first-generation assays, without prior IIF, is a valuable alternative to the consensus algorithm. 29 However, especially in patients with a relatively low pre-test probability (<0.4), i.e. clinical manifestations that are less specific for AAV, an added value of IIF could be observed. Contrary to this study's indication, removal of IIF from the ANCA algorithm is not supported by the ANCA expert laboratories worldwide. Indeed, all 27 responding laboratories continued to have IIF in their algorithm. Interestingly, 2 out of these 27 laboratories performed ANCA screening by antigen-specific tests being followed by IIF. The major drawback of this approach, as well as of leaving out IIF completely, is the role of ANCA testing in the diagnosis of inflammatory bowel diseases and autoimmune liver diseases. 30 For the correct positioning of ANCA IIF in the testing algorithm, it is of great importance that the laboratory can distinguish ANCA requests for AAV from ANCA requests for other clinical diagnoses. In the latter case, testing for ANCA by IIF is mandatory, follow-up testing for PR3-and MPO-ANCA is superfluous, and testing for other specificities is of limited value (Figure 3(b) ). Especially testing for Figure 3 Distinct scenarios for ANCA algorithms for AAV (a) and inflammatory bowel disease/autoimmune liver diseases (b). Scenario A shows the minimal requirement of the 1999 international consensus (screening by IIF and, if positive, antigen-specific immunoassays). Scenario B shows the optimal requirement of the international consensus (IIF and antigen-specific immunoassays) on all samples. Scenario C shows the inversed scheme of the minimal requirements of the international consensus (screening by antigen-specific immunoassays and, if positive, IIF). Scenario D shows a scheme in which IIF is considered redundant (only antigen-specific immunoassays). In case of scenario C and D it is mandatory that requests for inflammatory bowel disease and autoimmune liver diseases (b) be separated from requests for AAV (scenario E; only IIF). ANCA: antineutrophil cytoplasmic antibodies; AAV: ANCA-associated vasculitides; IIF: indirect immunofluorescence.
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PR3
-ANCA in these conditions may be confusing since a number of patients, in particular those with ulcerative colitis and primary sclerosing cholangitis, may have or develop PR3-ANCA. [31] [32] [33] Typically, these sera reveal a P-ANCA by IIF. From the questionnaires, it appears that a substantial number of laboratories do not differentiate between these disease entities and the same algorithm that is designed for the detection of ANCA in relation to AAV is applied. Other laboratories offer distinct request possibilities (AAV versus gastroenterology) on their request form and adjust their testing algorithm accordingly, for instance by including IIF on formalin-fixed neutrophils in case of a gastroenterology request. As depicted in Figure 3 , there are currently four scenarios for ANCA testing in AAV. Scenario A is according to the international consensus (minimal requirement), i.e. IIF followed by antigen-specific immunoassays, scenario B performs IIF and antigen-specificity simultaneously, scenario C is to screen by antigen-specific immunoassays followed by IIF, and scenario D is to use only antigenspecific immunoassays. Test characteristics of the ANCA assays available in the laboratory will eventually determine the best choice. The best option is based on high sensitivity of the first assay in the algorithm. If antigen-specific immunoassays indeed appear to have proven better sensitivity, scenarios B-D are preferred. For scenarios C and D, distinction of requests for inflammatory bowel diseases and autoimmune liver diseases will be mandatory. Next, the best choice between scenarios B-D is based on the test with the best specificity. If this happens to be the antigen-specific immunoassays, the added value for ANCA IIF in the diagnosis of AAV has come to an end, and scenario D is the option of choice.
ANCA quantity for diagnosis and follow-up
According to the international consensus, ANCA quantitation is optional both for IIF as well as antigen-specific assays. 2 Nevertheless, quantitation may have added value for several reasons. 34 First, the likelihood ratio of a positive ANCA result for the diagnosis of AAV increases with higher testresult intervals. 35 On the other hand, quantitative ANCA results may also be of benefit for follow-up. Especially patients with very severe AAV may require plasmapheresis and the efficacy of this therapy can be monitored by repetitive ANCA measurements. The discussion whether increased ANCA titers can predict clinical relapses in AAV patients is still ongoing. A meta-analysis was not conclusive and this was attributed to inter-laboratory methodological differences. 36 A more recent study revealed that routine ANCA monitoring in AAV patients is of limited value. However, in case of high pre-test probability, determination of ANCA levels may be useful. 37 This may be in line with our recent finding that ANCA rises are a predictor for relapses, particularly in AAV patients with renal involvement. 38 Standardization of assays may be an important pre-requisite for finalizing the discussion on the predictive value of increasing ANCA titers. In particular for PR3-ANCA, the correlation of quantitative results between distinct assays is poor. This is exemplified by our data obtained during the replacement of the first-generation FEIA by the third-generation FEIA. In case of positive results (both diagnostic and follow-up samples) obtained by the novel third-generation FEIA, the most recent historical sample, originally analyzed by the first-generation FEIA, was re-analyzed by the third-generation FEIA. Samples that had to be diluted further than the standard dilution were excluded because, in general, quantification of autoantibodies in various immunoassays are rarely linear upon dilution of samples. Within a time frame of three months, 58 samples were analyzed in both generations of PR3-ANCA assays and 25 samples in both generations of MPO-ANCA assays. As can be seen in Figure 4 , there is no correlation (r ¼ 0.09) between the PR3-ANCA values. This may be due to the distinct epitope exposition in both assay formats. The correlation (r ¼ 0.79) between the MPO-ANCA values, however, is much better. Apparently, the availability of the antigenic epitopes is less dependent on the method of antigen binding to the solid phase. The structure of MPO has been identified as a homodimer consisting of two heavy and two light chains. Therefore, it can be speculated that this homodimeric conformation and relevant epitopes are available for autoantibody binding after they are bound to the solid-phase matrix and this results in a good correlation between both MPO-ANCA methods. An increasing number of companies have calibrated their methods against the Centers for Disease Control and Prevention (CDC; Atlanta, GA, USA) reference sera for PR3-and MPO-ANCA and therefore antigen-specific results can be expressed in IU/ml. These include FEIA (Thermo-Fisher, Freiburg, Germany), capture ELISA (Eurodiagnostica, Malmo¨, Sweden), CLIA (Inova, San Diego, CA, USA), and even the Diagnostic ANCA algorithms in daily clinical practice: evidence, experience, and effectiveness TY Avery et al.
CytoBead IIF test (Generic Assays). 11, 15, 39 Unfortunately, this has not resulted in similar results in sera tested by distinct methods from different manufacturers (personal experience). Also the Institute for Reference Material and Methods (IRMM) is involved in preparing reference sera. The mission of the IRMM is to promote a common and reliable European measurement system in support of European Union policies. 40 While reference material for MPO-ANCA is already available, reference material for PR3-ANCA is in the pipeline. Whether these reference materials result in better alignment of different methods remains to be determined.
Conclusions
As summarized above, ANCA diagnostics have undergone many new technical developments. This has raised questions with respect to the international consensus algorithm that is based on screening by IIF and follow-up testing for PR3and MPO-ANCA by ELISA. 2 The positioning of ANCA IIF may become clear when the data of a large multicenter study become available (Damoiseaux et al., manuscript in preparation) . In this study, most of the new developments in ANCA methodologies have been incorporated and receiver operating characteristic (ROC) curve analysis may reveal the optimal way to test for ANCA in relation to AAV. For the autoimmune liver and inflammatory bowel diseases, ANCA IIF will prevail. It is anticipated that the new dataset eventually will result in a novel consensus on ANCA diagnostics. Whatever the eventual choice for a consensus algorithm, incidental clinical situations will warrant the use of additional ANCA methods. Obviously, this requires optimal interaction between the clinician and the diagnostic laboratory specialist. The positioning of reference material will be the next step in optimizing ANCA testing for diagnosis and follow-up. This may be of help in the ongoing discussion on the risk of ANCA rises for the development of clinical relapses.
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